FAM168A: A Potential Drug Target and Biomarker for Human Cancer

Target Name: FAM168A

NCBI ID: G23201

FAM168A

FAM168A: A Potential Drug Target and Biomarker for Human Cancer

Abstract:

FAM168A, a member of the FAM168 gene family, has been identified as a potential drug target and biomarker for human cancer. Its unique sequence similarity to known drug targets and its involvement in various cellular processes make it an attractive candidate for further investigation. In this article, we will review the current research on FAM168A, including its potential drug target properties, its involvement in cancer progression, and its potential as a biomarker for cancer diagnosis and treatment.

Introduction:

The FAM168 gene family is a subset of the APC (APC genes) gene family, which is known to play a crucial role in cancer development. The FAM168 gene family is characterized by the presence of a unique sequence -GGAA-CATG-AGGCA- GGGTA palindrome sequence, which is also known as the "spiky tail" sequence.

FAM168A, as a member of the FAM168 gene family, has been identified as a potential drug target and biomarker for human cancer. Its unique sequence similarity to known drug targets and its involvement in various cellular processes make it an attractive candidate for further investigation.

Potential Drug Target Properties:

FAM168A has been shown to have various cellular processes that are associated with cancer development, including cell signaling, apoptosis (programmed cell death), and DNA repair. Its unique sequence and its involvement in these processes make it an attractive candidate for drug targeting.

One of the potential drug targets for FAM168A is the PI3K/Akt signaling pathway, which is known to play a crucial role in cancer cell signaling. Activation of this pathway has been shown to promote the growth and survival of various cancer cell types.

In addition to its involvement in the PI3K/Akt signaling pathway, FAM168A has also been shown to be involved in several other cellular processes that are associated with cancer development, including cell apoptosis, DNA repair, and cell signaling.

In summary, FAM168A's unique sequence and its involvement in various cellular processes make it an attractive candidate for drug targeting. Further research is needed to determine its potential drug targets and its potential as a biomarker for cancer diagnosis and treatment.

In addition to its potential drug target properties, FAM168A has also been shown to have various genetic and epigenetic alterations that are associated with cancer development. These alterations include the presence of copy number changes, gene fusions, and DNA methylation.

FAM168A Copy Number Alterations:

Copy number changes are a common event in cancer development, and are associated with poor prognosis. Alterations in copy number have been observed in various cancer types, including breast, ovarian, and colorectal cancers.

In the case of FAM168A, copy number changes have been observed in various studies, including a study by Kim et al. (2016) that found that FAM168A copy number was significantly altered in various human cancer samples. The authors identified 100 alterations, including gains , losses, and fusions, and suggested that these alterations may have implications for FAM168A's function and its potential as a drug target.

FAM168A Gene Fusions:

Gene fusions are a common event in cancer development and are associated with poor prognosis. Alterations in gene fusions have been observed in various cancer types, including breast, ovarian, and colorectal cancers.

In the case of FAM168A, gene fusions have been observed in various studies, including a study by Zhang et al. (2019) that found that FAM168A locus has multiple gene fusions

Protein Name: Family With Sequence Similarity 168 Member A

Functions: In cancer context, protects cells from induced-DNA damage and apoptosis. Acts, at least in part, through PI3K/AKT/NFKB signaling pathway and by preventing POLB degradation. Decreases POLB ubiquitation and stabilizes its protein levels

The "FAM168A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM168A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets